|Articles|June 15, 2021
Process Development Improvements Post-Pandemic
Author(s)BioPharm International Editors
What can the biopharma industry learn from its rapid response to the COVID-19 pandemic?
Advertisement
In this expert interview with BioPharm International, James Blackwell, president of The Windshire Group, LLC, explains key actions the biopharma can learn from its response to the COVID-19 pandemic that can be applied to improve process development for non-pandemic development programs.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
5